Drug intelligence / Profile preview

kobotide

Development stage
Phase 4
Modality
Peptides
Administration
Not Established (preclinical; Routes Such As Topical Or Parenteral Are Possible Based On Modality)
01

Overview

Kobotide is a synthetic peptide derived from the venom of the Chinese red-headed centipede (Scolopendra subspinipes mutilans). It is classified as an antimicrobial peptide and has demonstrated potent antibacterial activity, particularly against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Kobotide exerts its effects by disrupting bacterial cell membranes, leading to cell death. In addition to its antimicrobial properties, preliminary research suggests it may have anti-inflammatory and immunomodulatory effects. Kobotide is primarily studied in preclinical settings for potential use as a novel antibiotic or anti-infective agent.

Beyond the preview

Go deeper on kobotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on kobotide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call